Cargando…

Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94

Amyloid-beta (Aβ) deposition is common in cognitively unimpaired (CU) elderly >85 years. This study investigated amyloid distribution and evaluated three published in vivo amyloid-PET staging schemes from a cognitively unimpaired (CU) cohort aged 84.9 ± 4.3 years (n = 75). SUV-based principal com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michalowska, Malgorzata M., Herholz, Karl, Hinz, Rainer, Amadi, Chinenye, McInnes, Lynn, Anton-Rodriguez, Jose M., Karikari, Thomas K., Blennow, Kaj, Zetterberg, Henrik, Ashton, Nicholas J., Pendleton, Neil, Carter, Stephen F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718666/ https://www.ncbi.nlm.nih.gov/pubmed/35858992 http://dx.doi.org/10.1038/s41380-022-01685-6

Ejemplares similares

APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly
por: Snellman, Anniina, et al.
Publicado: (2023)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

A Non-APOE Polygenic Risk Score for Alzheimer’s Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds
por: Skoog, Ingmar, et al.
Publicado: (2021)

Amyloid beta associations with connected speech in cognitively unimpaired adults
por: Mueller, Kimberly D., et al.
Publicado: (2021)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score
por: Tomassen, Jori, et al.
Publicado: (2022)

Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)

Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals
por: Cedres, Nira, et al.
Publicado: (2022)

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals
por: Brugulat-Serrat, Anna, et al.
Publicado: (2023)

Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results
por: Largent, Emily A., et al.
Publicado: (2020)

Reasons for undergoing amyloid imaging among cognitively unimpaired older adults
por: Ryan, Mary M., et al.
Publicado: (2021)

The Association of Plasma Amyloid-β and Cognitive Decline in Cognitively Unimpaired Population
por: Wang, Jin, et al.
Publicado: (2022)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly
por: Hahn, Andreas, et al.
Publicado: (2019)

Associations of Widowhood and β-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults
por: Biddle, Kelsey D., et al.
Publicado: (2020)

The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults
por: Insel, Philip S., et al.
Publicado: (2020)

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
por: Collij, Lyduine E., et al.
Publicado: (2021)

Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults
por: Insel, Philip S., et al.
Publicado: (2021)

Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
por: Karikari, Thomas K., et al.
Publicado: (2018)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Differential requirement of GRP94 and GRP78 in mammary gland development
por: Zhu, Genyuan, et al.
Publicado: (2014)

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism
por: Mattsson, Niklas, et al.
Publicado: (2010)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Dual-phase [18F]florbetapir in frontotemporal dementia
por: Asghar, Michael, et al.
Publicado: (2018)

Protective Effects of Glucose-Related Protein 78 and 94 on Cisplatin-Mediated Ototoxicity
por: Yi, Junyeong, et al.
Publicado: (2020)

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021)

Prodromal frontotemporal dementia: clinical features and predictors of progression
por: Benussi, Alberto, et al.
Publicado: (2021)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults
por: Akinci, Muge, et al.
Publicado: (2022)

Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults
por: Malek-Ahmadi, Michael, et al.
Publicado: (2023)

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Clinical utility of an antibody‐free LC‐MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study
por: Allué, José Antonio, et al.
Publicado: (2023)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults
por: Arenaza-Urquijo, Eider M., et al.
Publicado: (2020)

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
por: Ossenkoppele, Rik, et al.
Publicado: (2022)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis
por: Padovani, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1qluvcr0i3qegugbas1qk8rlh